Loading
Diabetes Treatment and Management / Chronic Kidney Disease and Diabetes / Liver Disease Diagnosis and Treatment · Journal article
Diabetes Obesity and Metabolism · August 17, 2026
A consensus or society position rather than new primary data.
This narrative review reappraises fibrates as potential adjunctive therapy for cardiovascular-kidney-liver-metabolic syndrome, emphasizing their PPAR-α activation and pleiotropic effects on inflammation, fibrosis, and vascular injury. The strongest clinical evidence supports fenofibrate in diabetic retinopathy (reducing progression and need for laser therapy), with weaker or limited evidence for nephropathy, neuropathy, peripheral arterial disease, and liver disease; the authors conclude that dedicated outcome trials and improved patient selection are needed before broader implementation.
Narrative review. Patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, obesity, and metabolic dysfunction-associated steatohepatitis (CKLM syndrome). Intervention: Fibrates (primarily fenofibrate) and selective PPAR-α modulators. Compared with: Contemporary therapies including SGLT2i, GLP-1 RAs, and nsMRA.
Fenofibrate reduces retinopathy progression and the need for retinal laser therapy in diabetic retinopathy Post hoc analyses suggest favourable effects on albuminuria progression and chronic estimated glomerular filtration rate (eGFR) decline Fibrates may cause a reversible rise in serum creatinine
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should be aware that fibrates, particularly fenofibrate, may have a complementary role in managing diabetic retinopathy within contemporary cardiometabolic therapy regimens. However, pending dedicated outcome trials, fibrates should not yet be implemented broadly; patient selection and evidence-based positioning relative to SGLT2i, GLP-1 RAs, and nsMRAs remain to be defined.
A narrative review synthesizing existing clinical evidence and mechanistic pathways to reappraise fibrate therapy within a proposed disease framework, intended to inform clinical thinking rather than report new trial results.
As stated by the source record.
Clinicians should be aware that fibrates, particularly fenofibrate, may have a complementary role in managing diabetic retinopathy within contemporary cardiometabolic therapy regimens. However, pending dedicated outcome trials, fibrates should not yet be implemented broadly; patient selection and evidence-based positioning relative to SGLT2i, GLP-1 RAs, and nsMRAs remain to be defined.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome. Although contemporary therapies such as sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and non‐steroidal mineralocorticoid receptor antagonists (nsMRA) have improved cardiovascular and renal outcomes, diabetes‐related microvascular complications remain common. Fibrates, traditionally used to lower triglycerides and increase high‐density lipoprotein cholesterol, activate peroxisome proliferator‐activated receptor‐α (PPAR‐α) and influence pathways involved in metabolic and vascular injury, including inflammation, oxidative stress, endothelial dysfunction, mitochondrial metabolism, lipid handling, fibrosis and angiogenesis. This review reappraises the potential role of fibrates within the CKLM syndrome framework, focusing on diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, peripheral artery disease and metabolic dysfunction‐associated steatotic liver disease. Clinical evidence is the strongest for diabetic retinopathy, where fenofibrate reduces retinopathy progression and the need for retinal laser therapy. Post hoc analyses also suggest favourable effects on albuminuria progression and chronic estimated glomerular filtration rate (eGFR) decline, although fibrates may cause a reversible rise in serum creatinine. Evidence for diabetic neuropathy remains limited, while clinical trials and real‐world studies suggest reductions in lower‐extremity amputations and diabetic foot complications. In liver disease, fenofibrate has shown modest benefit, whereas selective PPAR‐α modulators may more favourably influence liver enzymes, inflammation and non‐invasive fibrosis markers. Overall, fibrates may complement contemporary cardiometabolic therapies by targeting residual microvascular and liver‐related risk. However, dedicated outcome trials and improved patient stratification are needed before broader clinical implementation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.